SG11202106716RA - Combination of selective alpha-adrenergic receptor agonist or an anticholinergic agent and lipoic acid and uses thereof - Google Patents

Combination of selective alpha-adrenergic receptor agonist or an anticholinergic agent and lipoic acid and uses thereof

Info

Publication number
SG11202106716RA
SG11202106716RA SG11202106716RA SG11202106716RA SG11202106716RA SG 11202106716R A SG11202106716R A SG 11202106716RA SG 11202106716R A SG11202106716R A SG 11202106716RA SG 11202106716R A SG11202106716R A SG 11202106716RA SG 11202106716R A SG11202106716R A SG 11202106716RA
Authority
SG
Singapore
Prior art keywords
combination
receptor agonist
adrenergic receptor
lipoic acid
anticholinergic agent
Prior art date
Application number
SG11202106716RA
Inventor
Mahesh Kandula
Original Assignee
Cellix Bio Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2019/050901 external-priority patent/WO2019150341A1/en
Application filed by Cellix Bio Private Ltd filed Critical Cellix Bio Private Ltd
Publication of SG11202106716RA publication Critical patent/SG11202106716RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
SG11202106716RA 2019-01-12 2020-01-03 Combination of selective alpha-adrenergic receptor agonist or an anticholinergic agent and lipoic acid and uses thereof SG11202106716RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201941001491 2019-01-12
PCT/IB2019/050901 WO2019150341A1 (en) 2018-02-05 2019-02-05 Combination of an antimuscarinic or an anticholinergic agent and lipoic acid and uses thereof
PCT/IB2020/050028 WO2020144546A1 (en) 2019-01-12 2020-01-03 Combination of selective alpha-adrenergic receptor agonist or an anticholinergic agent and lipoic acid and uses thereof

Publications (1)

Publication Number Publication Date
SG11202106716RA true SG11202106716RA (en) 2021-07-29

Family

ID=71520752

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106716RA SG11202106716RA (en) 2019-01-12 2020-01-03 Combination of selective alpha-adrenergic receptor agonist or an anticholinergic agent and lipoic acid and uses thereof

Country Status (7)

Country Link
US (1) US20220096467A1 (en)
EP (1) EP3883544A4 (en)
JP (1) JP2022516796A (en)
AU (1) AU2020206010A1 (en)
CA (1) CA3126328A1 (en)
SG (1) SG11202106716RA (en)
WO (1) WO2020144546A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200118128A (en) * 2018-02-05 2020-10-14 셀릭스 바이오 프라이빗 리미티드 Combination of antimuscarinic or anticholinergic and lipoic acid and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
CN1960735B (en) * 2004-05-20 2015-07-29 代阿麦迪卡股份有限公司 The application of drug regimen in treatment insulin resistance
PT1965787E (en) * 2005-11-30 2013-07-05 Endo Pharmaceuticals Inc Treatment of xerostomia with a sulfur-containing antioxidant
PT2821405E (en) * 2009-06-15 2016-06-14 Encore Health Llc Choline esters for treating presbyopia and cataract
US20120076738A1 (en) * 2010-09-28 2012-03-29 Michael Graeber Combination treatment for dermatological conditions
EP2645993B1 (en) * 2010-12-03 2016-11-02 Allergan, Inc. Pharmaceutical cream compositions comprising oxymetazoline
KR101586789B1 (en) * 2012-12-28 2016-01-19 주식회사 종근당 Sustained-release lipid pre-concentrate of cationic pharmacologically active substance and pharmaceutical composition comprising the same
BR112020009364A2 (en) * 2017-11-17 2020-10-27 Cellix Bio Private Limited compound, pharmaceutical composition, method for treating a vision disorder or a complication of it in an individual in need of it and method for treating a skin disease or a complication thereof in an individual in need of it
KR20200118128A (en) * 2018-02-05 2020-10-14 셀릭스 바이오 프라이빗 리미티드 Combination of antimuscarinic or anticholinergic and lipoic acid and uses thereof

Also Published As

Publication number Publication date
CA3126328A1 (en) 2020-07-16
EP3883544A1 (en) 2021-09-29
JP2022516796A (en) 2022-03-02
EP3883544A4 (en) 2022-09-14
AU2020206010A1 (en) 2021-07-22
US20220096467A1 (en) 2022-03-31
WO2020144546A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
IL276350A (en) Combination of an antimuscarinic or an anticholinergic agent and lipoic acid and uses thereof
IL283362A (en) Thrβ receptor agonist compound and preparation method and use thereof
IL280984A (en) Tropomyosin receptor kinase (trk) degradation compounds and methods of use
IL285254A (en) Compositions containing, methods and uses of antibody-tlr agonist conjugates
SG11202011513RA (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
ZA202106304B (en) Heterocyclic compound and use thereof
SG11202102651SA (en) Farnesoid x receptor agonists and uses thereof
EP3825308C0 (en) Thiohydantoin compound, composition, and use thereof as androgen receptor antagonists
ZA202102263B (en) Oral formulations of kappa opioid receptor agonists
IL281474A (en) Farnesoid x receptor agonists and uses thereof
EP4069726A4 (en) Glp2 receptor agonists and methods of use
IL283968A (en) Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
SG11202105577TA (en) Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use
SG11202106716RA (en) Combination of selective alpha-adrenergic receptor agonist or an anticholinergic agent and lipoic acid and uses thereof
PL3429993T3 (en) Dopamine d3 receptor selective antagonists/partial agonists; method of making; and use thereof
EP3664806A4 (en) Apelin receptor agonists and methods of use thereof
EP3313396A4 (en) G protein-coupled receptor kinase inhibitors and methods for use of the same
GB201810746D0 (en) Use of sclerostin antagonist
ZA202007347B (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
SG11202107919YA (en) The monohydrate of rogaratinib hydrochloride and solid states thereof
GB2603330B (en) Heterocyclic THR-B receptor agonist compound and preparation method and use therefor
HK1247105A1 (en) Combination dosage form of a mu opioid receptor antagonist and an opioid agent
EP3730137A4 (en) Therapeutic agent for glaucoma comprising fp agonist and blocker
PT3507287T (en) Substituted n-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide and n-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide derivatives p2x7 receptor antagonists
EP4212159A4 (en) Use of sphingosine-1-phosphate receptor agonist